DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA Arzneimittel AG: Change in leadership at STADA
05.06.2016 / 19:02
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Change in leadership at STADA
- Hartmut Retzlaff lays down office as Chief Executive Officer due to
medical reasons.
- Executive Board members Helmut Kraft and Dr. Matthias Wiedenfels
jointly take over areas of responsibility previously overseen by the
CEO
- Dr. Matthias Wiedenfels initially appointed Chief Executive Officer
Bad Vilbel, June 5, 2016 - The Supervisory Board of STADA Arzneimittel AG
has decided on a change at the company's helm at an extraordinary meeting
held today. Due to a serious, long-term illness, the previous Chief
Executive Officer Hartmut Retzlaff has to lay down his office with
immediate effect until further notice. His existing duties will be assumed
by the Executive Board members Hartmut Kraft and Dr. Matthias Wiedenfels.
Initially Dr. Matthias Wiedenfels has also been appointed as Chief
Executive Officer.
"Hartmut Retzlaff has shaped STADA. In his 23 years as CEO to date, he has
successfully built and internationalized the company and diversified it
unswervingly. STADA is now in better shape than ever. The fact that Mr.
Retzlaff has been forced to lay down his office temporarily due to medical
reasons comes as a surprise to us and saddens us deeply. But health has top
priority. Together with all employees of STADA, the Supervisory Board
wishes him a good and speedy recovery," said Dr. Martin Abend, Chairman of
the Supervisory Board.
Helmut Kraft, who has been on the Executive Board since 2010 and is
responsible for Finance, will also take charge of Marketing & Sales,
Purchasing/Supply Chain Management as well as Research & Development. Dr.
Matthias Wiedenfels, who has been the member of the Executive Board
responsible for Corporate Development & Central Services since 2013, will
also be in charge of Corporate Strategy, Corporate Communication as well as
Production. Until further notice Dr. Matthias Wiedenfels will also take
over as Chief Executive Officer.
Dr. Martin Abend stated about the appointment: "With Matthias Wiedenfels,
an experienced, long-serving manager is initially taking over at the helm
of the Executive Board. He has played an influential part in the group's
positive development in the past years and he will consequently drive
forward the initiated change for the benefit of the company. With that he
stands for continuity as well as the ability to give the company the
continuously necessary new impulses. We are sure that STADA will continue
to develop exceptionally successful, not only because of a growth strategy
that is acknowledged in the market and with highly motivated employees."
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de
Or visit us in the Internet at www.stada.com.
---------------------------------------------------------------------------
05.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart; Terminbörse EUREX
End of News DGAP News Service
---------------------------------------------------------------------------
469245 05.06.2016
DGAP-News: STADA Arzneimittel AG: Change in leadership at STADA
| Source: EQS Group AG